Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Detailed price information for Dyne Therapeutics Inc (DYN-Q) from The Globe and Mail including charting and trades.
Nasdaq

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 in Myotonic Dystrophy Type 1, Anticipates U.S. Accelerated Approval Submission in H1 2026

Dyne Therapeutics announces FDA Fast Track designation for DYNE-101, targeting myotonic dystrophy type 1 with potential accelerated approval in 2026. Dyne Therapeutics has announced that its ...
Seeking Alpha

Dyne Therapeutics: Emergence As A Superior DM1/DMD Player Warrants Rating Upgrade

Upgrading Dyne Therapeutics to 'Buy' due to promising late-stage DM1 and DMD drug candidates and significant unmet need in both indications. Recent management changes and a more measured clinical ...
The National Law Review

Investor Conference Call and Webcast

The webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne’s website, and a replay will be accessible for 90 days following the presentation. An ...
Seeking Alpha

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen ...

WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc (DYN). (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically ...